A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms TOURMALINE-MM2
- Sponsors Takeda Oncology
- 28 Jul 2022 Status changed from active, no longer recruiting to completed.
- 27 May 2022 Planned End Date changed from 30 Apr 2022 to 30 Jun 2022.
- 09 Apr 2022 This trial has been completed in France , according to European Clinical Trials Database record.